Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03811652 · ClinicalTrials.gov registry record · Phase 1
A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT03811652 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 8 participants.
The verdict
NCT03811652, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further evaluation of MEDI7247 in patients with selected advanced or metastatic solid tumor malignancies that have received at least 1 prior line of treatment.
Interventions
- DRUG MEDI7247
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2018-12-20 |
| Est. Completion | 2019-12-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03811652
The ClinicalTrials.gov registry entry for NCT03811652 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI7247 is the first listed.
NCT03811652 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03811652 about?
NCT03811652 is a clinical study titled "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors". To assess safety and tolerability, describe the dose-limiting toxicities, assess the preliminary antitumor activity, determine the maximum tolerated dose (MTD) or the highest protocol-defined dose (maximum administered dose) in the absence of establishing the MTD, and a recommended dose for further ...
What is the current status of trial NCT03811652?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2018-12-20. Estimated completion is 2019-12-10.
What interventions are being tested in trial NCT03811652?
The interventions under investigation include: MEDI7247 (DRUG).
Who is sponsoring clinical trial NCT03811652?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.